Page last updated: 2024-09-05

erlotinib hydrochloride and ly2334737

erlotinib hydrochloride has been researched along with ly2334737 in 1 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)
Trials
(erlotinib hydrochloride)
Recent Studies (post-2010)
(erlotinib hydrochloride)
Studies
(ly2334737)
Trials
(ly2334737)
Recent Studies (post-2010) (ly2334737)
4,3537863,03314513

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO1

Trials

1 trial(s) available for erlotinib hydrochloride and ly2334737

ArticleYear
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-15, Volume: 17, Issue:18

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult

2011